María Fernanda García

Dr. María Fernanda García

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2017 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
Marcos CoutoMarcos Couto
Marcos Couto
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
CACatalina Alamón
Catalina Alamón
MCMauricio Cabrera
Mauricio Cabrera
PCPablo Cabral
Pablo Cabral
ICMAB-CSIC Viñas TeixidorICMAB-CSIC Viñas Teixidor
ICMAB-CSIC Viñas Teixidor

1 March 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
XZXiuli Zhang
Xiuli Zhang
MSManankumar Shah
Manankumar Shah
JNJessica Newton-Northup
Jessica Newton-Northup
PCPablo Cabral
Pablo Cabral
TQThomas Quinn
Thomas Quinn

5 June 2020 in Cells
Verified
Journal Article
Open access
PDF file
Marcos CoutoMarcos Couto
Marcos Couto
CACatalina Alamón
Catalina Alamón
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
MKMariángeles Kovacs
Mariángeles Kovacs
Emiliano TriasEmiliano Trias
Emiliano Trias
HCHugo Cerecetto
Hugo Cerecetto
One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a variety of cancers are initially susceptible to chemotherapy, they eventually develop multi-drug resistance. Anti-tumor agents overcoming resistance and acting through two or more ways offer greater therapeutic benefits over single-mechanism entities. In this study, we report on a new family of bifunctional compounds that, offering the possibility of dual action (drug + radiotherapy combinations), may result in significant clinical benefits. This new family of compounds combines two fragments: the drug fragment is a lapatinib group, which inhibits the tyrosine kinase receptor activity, and an icosahedral boron cluster used as agents for neutron capture therapy (BNCT). The developed compounds were evaluated in vitro against different tyrosine kinase receptors (TKRs)-expressing tumoral cells, and in vitro–BNCT experiments were performed for two of the most promising hybrids, 19 and 22. We identified hybrid 19 with excellent selectivity to inhibit cell proliferation and ability to induce necrosis/apoptosis of glioblastoma U87 MG cell line. Furthermore, derivative 22, bearing a water-solubility-enhancing moiety, showed moderate inhibition of cell proliferation in both U87 MG and colorectal HT-29 cell lines. Additionally, the HT-29 cells accumulated adequate levels of boron after hybrids 19 and 22 incubations rendering, and after neutron irradiation, higher BNCT-effects than BPA. The attractive profile of developed hybrids makes them interesting agents for combined therapy.

18 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Catalina AlamónCatalina Alamón
Catalina Alamón
BDBelén Lourdes Dávila
Belén Lourdes Dávila
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
CSCarina Sánchez
Carina Sánchez
MKMariángeles Kovacs
Mariángeles Kovacs
HCHugo Cerecetto
Hugo Cerecetto
Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together, have been proposed as future therapeutic strategies. In this sense in our ongoing project of developing new anti-glioblastoma drugs, we identified a sunitinib-carborane hybrid agent, 1, with both in vitro selective cytotoxicity and excellent BNCT-behavior. Consequently, we studied the ability of compound 1 to inhibit TKRs, its promotion of cellular death processes, and its effects on the cell cycle. Moreover, we analyzed some relevant drug-like properties of 1, i.e., mutagenicity and ability to cross the blood–brain barrier. These results encouraged us to perform an in vivo anti-glioblastoma proof of concept assay. It turned out to be a selective FLT3, KIT, and PDGFR-β inhibitor and increased the apoptotic glioma-cell numbers and arrested sub-G1-phase cell cycle. Its in vivo activity in immunosuppressed mice bearing U87 MG human glioblastoma evidenced excellent anti-tumor behavior.

15 January 2013 in Oncology
Verified
Journal Article
Closed access
XCXimena Camacho
Ximena Camacho
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
VCVictoria Calzada
Victoria Calzada
MFMarcelo Fernández
Marcelo Fernández
JCJose A. Chabalgoity
Jose A. Chabalgoity
PCPablo Cabral
Pablo Cabral
Introduction: Vascular endothelial growth factor (VEGF) is one of the classic factors to tumor-induced angiogenesis in several tumor types, including melanoma. Bevacizumab, a monoclonal antibody against VEGF, could be used as an imaging tool in preclinical studies. Objective: To radiolabel bevacizumab with [99mTc(CO)3(OH2)3]+ and evaluate it in vivo and in vitro for melanoma imaging properties. Methods: Bevacizumab was radiolabeled with [99mTc(CO)3(OH2)3]+ ion in saline. The radiochemical stability of the labeled antibody was assessed. The biodistribution and scintigraphy imaging of the radiolabeled antibody were evaluated in normal C57BL/6J mice and in C57BL/6J mice bearing murine B16F1 melanoma tumors. Immunoreactivity of bevacizumab to murine tumors was determined from direct immunofluorescence and immunoblotting assays. Results: We demonstrate that 99mTc(CO)3-bevacizumab was stable. In vivo biodistribution studies revealed that tumor uptake of 99mTc(CO)3-bevacizumab was 2.64 and 2.51 %ID/g at 4 and 24 h postinjection. Scintigraphy image studies showed tumor selective uptake of 99mTc(CO)3-bevacizumab in the tumor-bearing mice. This affinity was confirmed by immunoassays performed on B16F10 tumor samples. Conclusions:99mTc(CO)3-bevacizumab could be used as an approach for tumor nuclear imaging in preclinical studies. This should be useful to provide insights into the angiogenic stimulus before and after chemotherapy, which might help improve current antitumor therapy.

4 April 2023 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CACatalina Alamón
Catalina Alamón
BDBelén Dávila
Belén Dávila
María Fernanda GarcíaMaría Fernanda García
María Fernanda García
SNSusana Nievas
Susana Nievas
MDMaría Alejandra Dagrosa
María Alejandra Dagrosa
Marcos CoutoMarcos Couto
Marcos Couto